Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082
- PMID: 23264295
- PMCID: PMC3526220
- DOI: 10.2337/dc12-1218
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082
Comment in
-
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.Diabetes Care. 2013 Jan;36(1):e13. doi: 10.2337/dc12-1436. Diabetes Care. 2013. PMID: 23264296 Free PMC article. No abstract available.
Comment on
-
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.Diabetes Care. 2012 Oct;35(10):2076-82. doi: 10.2337/dc12-0199. Epub 2012 Jun 11. Diabetes Care. 2012. PMID: 22688551 Free PMC article. Clinical Trial.
Similar articles
-
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.Diabetes Care. 2013 Jan;36(1):e13. doi: 10.2337/dc12-1436. Diabetes Care. 2013. PMID: 23264296 Free PMC article. No abstract available.
-
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.Diabetes Care. 2013 Jun;36(6):e80. doi: 10.2337/dc12-2220. Diabetes Care. 2013. PMID: 23704688 Free PMC article. No abstract available.
-
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.Diabetes Care. 2012 Oct;35(10):2076-82. doi: 10.2337/dc12-0199. Epub 2012 Jun 11. Diabetes Care. 2012. PMID: 22688551 Free PMC article. Clinical Trial.
-
New treatments for type 2 diabetes--the DPP4 inhibitors.Prim Care Diabetes. 2007 Dec;1(4):209-11. doi: 10.1016/j.pcd.2007.10.004. Epub 2007 Dec 3. Prim Care Diabetes. 2007. PMID: 18632049 Review.
-
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358. Pharm Unserer Zeit. 2010. PMID: 20196038 Review. German. No abstract available.
Cited by
-
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.Diabetes Care. 2013 Jan;36(1):e13. doi: 10.2337/dc12-1436. Diabetes Care. 2013. PMID: 23264296 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical